LFCR · Lifecore Biomedical, Inc. De
Market Cap
$155.95M
Shares
37.85M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.12
Open$4.14
Day$4.06–4.19
52W close$3.66–8.82
Avg vol 30d139K
Short int2.4M · 6.4% float · 23.2d
Short vol62%
Last earningsAug 5, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 7 wks
filed Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+0.5%
Year over year
Operating margin
-13.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-5.0%
Year over year · fewer shares
Price change (1Y)
-47.0%
Trailing year
Short interest
6.4%
Latest settlement · 23.2 days to cover
AI Brief
Q4 FY26 earnings call · Mar 16, 2026
Q4 FY26
TL;DR. Lifecore reaffirmed 2026 guidance and continued adding pipeline wins (13 new programs with eight late-stage in the past 12 months) while expanding late-stage development toward commercialization, but Q2 2026 results deteriorated, with revenue down 6.2% year-over-year, six-month revenue down 19.9%, a wider net loss, and a previously targeted 2026 commercial launch delayed to 2028 due to customer funding challenges.
Bullish
- + Reaffirmed full-year 2026 guidance of $120–$125M revenue and $20.5–$25M Adjusted EBITDA
- + Added 13 new programs over the last 12 months, including eight late-stage programs
Bearish
- − Q2 2026 revenue fell 6.2% year-over-year to $34.2M and six-month revenue fell 19.9% to $57.4M
- − 2026 commercial launch delayed to 2028 due to customer funding challenges
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Mentioned in fund letters
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Weak
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−30%
below
Price vs 50-day avg
−10%
below
RSI (14)
38
neutral
MACD trend
Negative
52-week position
9%
near low
Momentum
relative strength
1-month return
−13%
trailing
6-month return
+2%
trailing
YTD return
−50%
this year
Relative strength
−15%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $6 — 200d above 50d
Institutional flow
Distributing
-6% holders QoQ · +14 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.40% of float · ▲ +0.3% MoM · 23.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
100 holders — mid 3-yr range
Squeeze score
59
elevated · 0–100
Fundamentals
Revenue growth
+6%
Y/Y
Gross margin
7%
contracting
EPS growth
−485%
Y/Y
Free cash flow
$-13.6M
Buyback
$3.8M
authorized
Balance sheet
$122.2M
net debt
Quant / Vol
risk profile
Volatility
60%
annualized · 1-yr
Max drawdown
−59%
past year
ATR
6.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
Revenue
· fiscal year 2029
Initiated
$212M – $225M
Adjusted EBITDA margin
· fiscal year 2029
Non-GAAP
Initiated
at least 25%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−30%
Bearish
Price vs 50-day avg
−10%
Bearish
RSI (14)
38
Neutral
MACD trend
Negative
Bearish
52-week position
9%
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $6 — 200d above 50d
Institutional flow
Distributing
-6% holders QoQ · +14 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.40% of float · ▲ +0.3% MoM · 23.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
100 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $4
Now $4 · 9%
Range high $9
vs 200-day avg -30%
vs 50-day avg -10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LFCR
this stock
Lifecore Biomedical, Inc. De
|
$155.95M | -49.6% | +6.4% | — | 6.4% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$58.31B | +17.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$44.03B | -8.9% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$43.22B | +18.8% | +4.3% | 60.8 | 3.2% |
|
HLN
Haleon plc
|
$40.41B | -9.1% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LFCR | -5.3% | -12.9% | +2.5% | -7.6% | -49.6% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -4.1% | -11.2% | -15.4% | -7.3% | -61.7% |
Capital returns
Buyback program
· as of Feb 26, 2023
Authorized
$3.80M
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1005286
CUSIP
514766104
13F (30d)
37 filings
37 filers
Visit website
Investor relations